Moderna’s COVID-19 Vaccine Shows Promise, Generating Positive Immune Responses in an Early Study
at the National Institutes of Health, involves 45 healthy people who received one of three different doses of the vaccine. According to Moderna, there are encouraging early signs that the shot generates antibodies against the COVID-19 virus, SARS-CoV-2, in levels that were similar to or higher than those seen in the plasma of people who recovered from infections.
The phase 1 study is actually not designed to measure effectiveness of the vaccine—it is is focused primarily on safety. Nevertheless, the hints of efficacy emerging from the trial are encouraging. The level of antibodies seen in the participants show that the vaccine can attract and awaken the body’s immune response to mount a defense against SARS-CoV-2. The data also hinted that the higher doses prompted stronger immune responses.
In addition, the company reports that in a preliminary analysis, antibodies from eight of the participants appeared to neutralize the virus in the lab. “Honestly we saw this data…and were pretty elated,” says Dr. Stephen Hoge, president of Moderna. It hit on almost every point we could hope for. What these results show is that the vaccine works to the best of anybody’s ability to test a vaccine prior to a [final] phase 3 study. And by works, we mean that it generated high quality, neutralizing antibody responses. The truth is, we’ve got a really product and potentially protective immune response here.
In the phase 1 study, the participants were all healthy volunteers aged 18 to 55 years. Those in the low- and medium-dose groups received two doses about a month apart, in order to properly prime the immune system for the most robust response. People in the highest dose group received only one inoculation. The results will likely be analyzed and reported in a scientific publication in coming weeks.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Coronavirus live updates: 'Positive' vaccine data lifts Moderna stock; Spain's GDP could fall more than 9.5%Covid-19 has now infected more than 4.7 million people around the world as of Monday, killing at least 315,496 people.
Weiterlesen »
Moderna's stock soars on positive early-stage data for its coronavirus vaccine candidateShares of Moderna Inc. jumped 25.1% in premarket trading on Monday after the biotechnology company announced positive results from a Phase 1 clinical trial for its experimental mRNA coronavirus vaccine. The trial was done in partnership with the National Institute of Allergy and Infectious Diseases. Within 43 days and after two doses, the participants taking one of two dosing levels of the vaccine candidate reported the same or higher level of antibodies as in blood samples gathered by patients who have recovered from COVID-19, the company said. There were four adverse events during the trial, including one participant who reported a severe skin reaction where the investigational vaccine was administered. "These interim Phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25" micrograms, Moderna chief medical officer Dr. Tal Zaks said in a news release. The next step is a Phase 2 trial, which has been approved to move forward by the Food and Drug Administration. It will focus on two dosing levels (50 microgram and 100 microgram). The early-stage trial had a third dosing level, 250 micrograms. Moderna's vaccine candidate is widely viewed as a frontrunner in the effort to develop the first vaccine for the virus. The preclinical company said earlier this month that the Phase 2 trial will begin "shortly," and on Monday it said it expects a Phase 3 trial to begin in July, if the vaccine is successful in the mid-stage trial. Moderna's stock has soared 240.9% year-to-date. The S&P 500 , in comparison, is down 11.3%.
Weiterlesen »
Early Results from Coronavirus Vaccine Trial Show Promising Immune ResponseHospital’s First Coronavirus Patient Discharged After Two Months\n
Weiterlesen »
Asia stocks set to trade higher as hopes of coronavirus vaccine riseStocks in Asia were set to open higher on Tuesday as hopes rise on a potential coronavirus vaccine after a positive development from a Moderna trial.
Weiterlesen »
Moderna Says Initial Covid-19 Vaccine Results Are PositiveModerna said human subjects in a Phase 1 trial of a candidate Covid-19 vaccine produced immune responses that were a positive sign of the vaccine’s potential to prevent infection with the new coronavirus
Weiterlesen »
Stocks making the biggest moves midday: Moderna, Delta, Bank of America, Best Buy, Disney & moreModerna shares spike on 'positive data' from its coronavirus vaccine trial. Netflix shares slip as investors rotate out of 'stay-at-home' stocks.
Weiterlesen »